Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2025-03-28 00:00:00 ET · period of report 2025-03-26 · accession 0000950170-25-046943 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-28 | 2025-03-26 | NAMS | Kling Douglas F | COO | S - Sale+OE | — | -16.5K | 44.0K | -27% | — |
| D | 2025-03-28 | 2025-03-26 | NAMS | Kling Douglas F | COO | M - OptEx | $0.00 | +16.5K | 60.5K | +38% | $0 |
| D | 2025-03-28 | 2025-03-26 | NAMS | Kling Douglas F | COO | A - Grant | — | +16.5K | 16.5K | New | — |
| D | 2025-03-28 | 2025-03-26 | NAMS | Kling Douglas F | COO | M - OptEx | — | -16.5K | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-03-26 | S | D | 16,539 | — | 44,000 | D | — | — | (F1) These shares were sold in multiple transactions at a price ranging from $22.75 to $23.20 per share. A portion of the ordinary shares were sold to satisfy tax withholding obligations arising upon the vesting of the restricted stock units ("RSUs"). The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Comission, upon request, full information regarding the number of shares sold in each transaction. |
| 2 | Common | Ordinary Shares | 2025-03-26 | M | A | 16,539 | $0.00 | 60,539 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2025-03-26 | A | A | 16,539 | — | 16,539 | D | — · — to — | 16,539 Ordinary Shares | (F4) The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. (F2) Each RSU represents a contingent right to receive one ordinary share. (F3) Upon grant, all of the RSUs were fully-vested. |
| 4 | Derivative | Restricted Stock Unit | 2025-03-26 | M | D | 16,539 | — | 0 | D | — · — to — | 16,539 Ordinary Shares | (F4) The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. (F2) Each RSU represents a contingent right to receive one ordinary share. (F3) Upon grant, all of the RSUs were fully-vested. |